Low mortality in fetal supraventricular tachycardia: Outcomes in a 30-year single-institution experience.
Edward T O'LearyMark E AlexanderVassilios J BezzeridesMonika DrogoszKatherine E EconomyKevin G FriedmanSarah S PickardWayne TworetzkyDouglas Y MahPublished in: Journal of cardiovascular electrophysiology (2020)
Fetuses with structurally normal hearts and sustained SVT can be effectively managed with transplacental drug therapy with minimal risk of intrauterine fetal demise. Treatment requires multiple antiarrhythmic agents in over half of cases. Later gestational age at fetal diagnosis and the presence of depressed fetal ventricular function, but not hydrops, predict postnatal arrhythmia burden.
Keyphrases
- gestational age
- catheter ablation
- birth weight
- preterm birth
- atrial fibrillation
- heart failure
- left ventricular
- preterm infants
- risk factors
- type diabetes
- adipose tissue
- cardiovascular disease
- stem cells
- cardiovascular events
- coronary artery disease
- metabolic syndrome
- mesenchymal stem cells
- body mass index
- drug induced
- cell therapy
- adverse drug